A practical reference on rodent models: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-12 and is reviewed periodically as new material appears.
In its usual supplied form, the peptide is a white to off-white lyophilized powder that dissolves readily in water and in aqueous buffers. Powder keeps far longer than solution, so material is normally shipped and stored dry, then dissolved only when needed. Once in solution, the chain is subject to hydrolysis and the liquid supports microbial growth, and practical guidance generally treats the dissolved form as short-lived. Containers should stay sealed and desiccated, because the powder takes up moisture from air.
Long-term storage of the dry powder is typically described at minus twenty degrees Celsius or colder, while shorter holding periods may use ordinary refrigeration. Repeated warming and cooling cycles are discouraged because they stress the material and can promote aggregation or loss. Light exposure and residual moisture are both treated as avoidable sources of degradation, and working aliquots are often prepared to limit how many times a container is opened. Sealed vials with a desiccant are the usual container.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Freeze-dried cake or loose powder after lyophilization |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are less durable than the powder |
| Typical storage temperature | Minus 20 degrees Celsius or below | Desiccated and protected from light; avoid repeated freeze-thaw cycles |
| Identity method | Electrospray mass spectrometry | Compared against the expected mass; paired with sequence or composition analysis |
| Purity method | Reverse-phase HPLC with ultraviolet detection | Reports main-peak percentage rather than peptide content by mass |
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
Once dissolved, the material is considerably less stable than the dry solid. Aqueous solutions are usually kept cold and used within a short window, and neutral or mildly acidic buffers are preferred over strongly alkaline conditions. Freeze-thaw cycles promote aggregation and loss of material to container surfaces, so dividing a batch into single-use aliquots is standard. Adsorption to plastic and glass can lower the measured concentration, meaning solution strength may need rechecking before an experiment.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
==== In vivo analysis ==== Glucose uptake in cells of organisms is measured with 2-deoxy-D-glucose or fluorodeoxyglucose. (18F)fluorodeoxyglucose is used as a tracer in positron emission tomography in oncology and neurology, where it is by far the most commonly used diagnostic agent.
==== Microspheres ==== An aqueous suspension of progesterone encapsulated in microspheres is marketed for use by intramuscular injection under the brand name ProSphere in Mexico. It is administered once weekly or once monthly, depending on the indication. For instance, the medication is administered at a dose of 100 to 300 mg by intramuscular injection once every 7 days for the treatment of threatened miscarriage. The microspheres range in size from 33 to 75 μg and are delivered using pre-filled syringes with a 20-gauge 38 mm needle. Peak levels of progesterone after a single 100 or 200 mg intramuscular injection of ProSphere occur after about 1.5 days. The elimination half-life of progesterone with this formulation is about 8 days. A single 200 mg intramuscular injection maintains progesterone levels of more than 10 ng/mL for 5 to 7 days. ProSphere is well tolerated in terms of injection site reactions. A combination of both estradiol and progesterone encapsulated within microspheres as an aqueous suspension for use by intramuscular injection has been marketed under the brand name Juvenum in Mexico. Studies of this formulation have been published. Estradiol and progesterone encapsulated in microspheres has been studied for use as a once-a-month combined injectable contraceptive but has not been further developed nor introduced for medical use.
=== 31 March === Seven people were killed by RSF shelling on the Abu Shouk camp. The RSF claimed to have taken Khor El Dalaib in South Kordofan following clashes that left 12 civilians dead. It also claimed to have killed 70 fighters of the Islamic Movement, and destroyed or captured 13 vehicles.
Sources: en.wikipedia.org
=== Drug Delivery === Microbubbles can serve as drug delivery vehicles in a variety of methods. The most notable of these include: (1) incorporating a lipophilic drug to the lipid monolayer, (2) attaching nanoparticles and liposomes to the microbubble surface, (3) enveloping the microbubble within a larger liposome, and (4) electrostatically bonding nucleic acids to the microbubble surface.
A Komodo dragon at London Zoo named Sungai laid a clutch of eggs in late 2005 after being separated from male company for more than two years. Scientists initially assumed she had been able to store sperm from her earlier encounter with a male, an adaptation known as superfecundation. On 20 December 2006, it was reported that Flora, a captive Komodo dragon living in the Chester Zoo in England, was the second known Komodo dragon to have laid unfertilised eggs: she laid 11 eggs, and seven of them hatched, all of them male. Scientists at Liverpool University in England performed genetic tests on three eggs that collapsed after being moved to an incubator, and verified Flora had never been in physical contact with a male dragon. After Flora's eggs' condition had been discovered, testing showed Sungai's eggs were also produced without outside fertilization. On 31 January 2008, the Sedgwick County Zoo in Wichita, Kansas, became the first zoo in the Americas to document parthenogenesis in Komodo dragons. The zoo has two adult female Komodo dragons, one of which laid about 17 eggs on 19–20 May 2007. Only two eggs were incubated and hatched due to space issues; the first hatched on 31 January 2008, while the second hatched on 1 February. Both hatchlings were males. Komodo dragons have the ZW chromosomal sex-determination system, as opposed to the mammalian XY system.
Brenner has developed targeted, quantitative analysis of the NAD+ metabolome and made fundamental contributions to NAD metabolism including discovery of nicotinic acid riboside-dependent NAD synthesis, elucidating the mechanism of synthesis of nicotinic acid adenine dinucleotide phosphate, and discovering multiple conditions in which NAD metabolism is dysregulated in disease. Brenner is active in translating NR technologies to treat and prevent human conditions that disturb the NAD system including cancer diabetic and chemotherapeutic peripheral neuropathy, heart failure, central brain injury, inflammation, mitochondrial myopathy pellagra, and infections such as coronavirus infection Brenner's work included the first human trial of NR in 2016, which demonstrated safe oral availability as an NAD+ precursor, thereby creating the foundational intellectual property for the NAD boosting industry. Though Brenner was the first to show that NR increases SIR2 activity, improves gene silencing, and can extend yeast lifespan, his work has not emphasized sirtuins or nonspecific anti-aging claims and instead emphasizes how NR repairs inflammatory conditions and metabolic stresses that dysregulate NAD+ and NADPH.
Sources: en.wikipedia.org
== W == Johannes Diderik van der Waals (1837–1923), Dutch physicist Sir James Walker (1863–1935), Scottish physical chemist John E. Walker (born 1941), British chemist, 1997 Nobel Prize in Chemistry Otto Wallach (1847–1931), German chemist, 1910 Nobel Prize in Chemistry John Warner (born 1962), American chemist, 2014 Perkin Medal, one of the "founders" of green chemistry Alfred Werner (1866–1919), Swiss chemist, 1913 Nobel Prize in Chemistry Thomas Summers West (1927–2010), British analytical chemist Peter Jaffrey Wheatley (1921–1997), English chemist Chaim Weizmann (1874–1952), Russian chemist, developed the ABE-process George M. Whitesides (born 1939), American chemist John Rex Whinfield (1901–1966), British chemist, discovered polyester fibres Otto Wichterle (1913–1998), Czech chemist, known for inventing modern contact lenses Heinrich Otto Wieland (1877–1957), German chemist 1927 Nobel Prize in Chemistry Julius Wilbrand (1839–1906), German chemist, inventor of TNT Harvey W.
== Early life and career == Cantelmo was a high school valedictorian. He graduated from Yale University with a degree in molecular biophysics and biochemistry. He worked for about 35 years in the pharmaceutical industry, specializing in high-performance liquid chromatography (HPLC). According to his own accounts and those of family members, he ran three HPLC companies. The last of these was GL Sciences. He left that position prior to the events of 2019. GL Sciences has stated it has no association with Cantelmoism or the use of illegal drugs. Cantelmo had a history of mental health difficulties and prior suicide attempts. He had also used other substances, including mescaline, LSD, and methamphetamine, at earlier points in his life.
A version branded Synacthen and provided in solution 250 mcg ampoules, for diagnostic uses, approved in 2008 and as of January 2017 controlled by Mallinckrodt. A version branded Synacthen, absorbed on to zinc phosphate, provided in milky white suspension, approved in 2008 and as of January 2017 controlled by Mallinckrodt.
Sources: en.wikipedia.org
The dry powder is the stable form and the dissolved form is comparatively fragile. Freezing a solution slows degradation but does not stop it, and repeated freezing and thawing adds further stress. Many laboratories therefore prepare small single-use portions rather than storing one large volume.
It describes the share of the chromatographic signal belonging to the main peak, not the mass fraction of peptide in the vial. Water, counter-ions such as acetate or trifluoroacetate, and residual solvents account for part of the weight of a lyophilized lot. Peptide content by mass is a separate measurement and is often reported alongside purity.
Mass spectrometry is the primary check, because the measured mass can be compared with the expected value for the fifteen-residue chain. Sequence analysis or amino acid composition provides an independent confirmation. Purity testing alone does not establish identity, since a mixture of unrelated short peptides can still produce a clean-looking chromatogram.
Bacteriostatic water or sterile saline is commonly used to dissolve the powder. The choice of solvent affects stability and preservation. Aqueous solutions are kept refrigerated and are not intended for long-term storage.